Tools
Tools
Liu, D, Kumar, S, Ashworth, J, Ali, K, Fadel, A, Guo, B and Slevin, M (2021) CD105 (Endoglin): A Potential Anticancer Therapeutic Inhibits Mitogenesis and Map Kinase Pathway Activation. Anticancer Research, 41 (3). pp. 1219-1229. ISSN 0250-7005
|
Text
Anticancer research.pdf - Published Version Download (1MB) | Preview |
Abstract
BACKGROUND: CD105 is highly expressed on human activated endothelial cells (ECs), is an important component of the TGF-β1 receptor complex and is essential for angiogenesis. CD105 expression is up-regulated in activated ECs and is an important potential marker for cancer prognosis. MATERIALS AND METHODS: In vitro rat myoblasts transfected with the L-CD105 and S-CD105 transfectants. The transfectants were treated with TGF-β1 for the angiogenesis study. RESULTS: L-CD105 affects cell proliferation in the presence and absence of TGF-β1, and inhibits p-ERK1/2, p-MEK1/2 and p-c-Jun in L-CD105 transfectants compared to controls. The induction of phospho-ERK1/2 following treatment with TGF-β1 remained significantly lower in L-CD105 transfectants compared to controls. CONCLUSION: L-CD105 inhibits the phosphorylation of ERK1/2, MEK1/2, c-Jun1/2/3, and associated signalling intermediates. CD105 modulates cell growth and TGF-β1 induced cell signalling through ERK-c-Jun expression.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | CD105; MAPK; TGF-β1; angiogenesis; cell signalling |
| Subjects: | Q Science > QP Physiology R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RS Pharmacy and materia medica |
| Divisions: | Sport & Exercise Sciences |
| Publisher: | International Institute of Anticancer Research |
| Related URLs: | |
| Date Deposited: | 30 Apr 2021 10:11 |
| Last Modified: | 04 Sep 2021 05:38 |
| DOI or ID number: | 10.21873/anticanres.14879 |
| URI: | https://researchonline.ljmu.ac.uk/id/eprint/14763 |
 |
View Item |